Literature DB >> 9070654

Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma.

L A James1, E L Mitchell, L Menasce, J M Varley.   

Abstract

Comparative genomic hybridisation has been used to map copy number changes in nine cases of ductal carcinoma in situ of the breast obtained from wax-embedded archive material. A wide variety of abnormalities were detected including gain of regions of 1q, 17q, 19q, 20p and 20q and loss on 13q, 14q, 17p, 16q and 22q. Amplification of areas on 10p, 8q and 20q were also observed. Chromosomal alterations were more frequent in higher grade DCIS and closely resemble those previously detected in invasive breast cancer using the same technique. These data provide strong molecular support for the view that DCIS is a precursor lesion of invasive breast carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9070654     DOI: 10.1038/sj.onc.1200923

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

2.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.

Authors:  J R Bischoff; L Anderson; Y Zhu; K Mossie; L Ng; B Souza; B Schryver; P Flanagan; F Clairvoyant; C Ginther; C S Chan; M Novotny; D J Slamon; G D Plowman
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

3.  Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.

Authors:  Shaoxi Liao; Mohamed M Desouki; Daniel P Gaile; Lori Shepherd; Norma J Nowak; Jeffrey Conroy; William T Barry; Joseph Geradts
Journal:  Genes Chromosomes Cancer       Date:  2012-08-09       Impact factor: 5.006

Review 4.  Advanced molecular cytogenetics in human and mouse.

Authors:  Kathleen Dorritie; Cristina Montagna; Michael J Difilippantonio; Thomas Ried
Journal:  Expert Rev Mol Diagn       Date:  2004-09       Impact factor: 5.225

5.  Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.

Authors:  Zining Jin; Lu Xu; Lei Zhang; Min Zhao; Dongbao Li; Lijun Ye; Ying Ma; Siyu Ren; Hailan Yu; Danyu Wang; Chunyan Liang; Bo Chen
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

6.  Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.

Authors:  M M Tanner; R A Karhu; N N Nupponen; A Borg; B Baldetorp; T Pejovic; M Fernö; D Killander; J J Isola
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

7.  Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization.

Authors:  Arezou A Ghazani; Nona Arneson; Keisha Warren; Melania Pintilie; Jane Bayani; Jeremy A Squire; Susan J Done
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

Review 8.  Do myoepithelial cells hold the key for breast tumor progression?

Authors:  Kornelia Polyak; Min Hu
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-07       Impact factor: 2.698

9.  Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts.

Authors:  E C Burt; L A James; M J Greaves; J M Birch; J M Boyle; J M Varley
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization.

Authors:  L A James; A M Kelsey; J M Birch; J M Varley
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.